Skip to main content
main-content
Erschienen in: Der Hautarzt 8/2010

01.08.2010 | Leitthema

Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors

Spektrum kutaner Nebenwirkungen

verfasst von: P.A. Gerber, B.A. Buhren, S. Kürle, Prof. Dr. B. Homey

Erschienen in: Die Dermatologie | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den letzten Jahren konnten Inhibitoren des epidermalen Wachstumsfaktorrezeptors (EGFR) wie Erlotinib, Gefitinib, Cetuximab oder Panitumumab erfolgreich in der Therapie verschiedener solider Tumoren etabliert werden. Als bedeutendste Nebenwirkung dieser sog. „targeted cancer drugs“ kommt es bei 45–100% der behandelten Patienten zu einem breiten Spektrum kutaner Toxizitäten. Diese umfassen neben einem charakteristischen papulopustulösen Exanthem unter anderem schmerzhafte Paronychien, eine Xerosis cutis, Pruritus und Haarwachstumsstörungen. Diese häufig stigmatisierenden Nebenwirkungen stellen eine ernst zu nehmende Gefahr für die Lebensqualität und nicht zuletzt für die Compliance der Patienten dar. Eine Dosisreduktion oder gar Unterbrechung der Tumortherapie können die Folge sein. Vor diesem Hintergrund und in Anbetracht der steigenden Anzahl von Patienten, die einer Therapie mit EGFR-Inhibitoren zugeführt werden, sind diese neuen medikamentenassoziierten Hautveränderungen für den klinischen Alltag von Dermatologen und Onkologen von zunehmender Bedeutung.
Literatur
1.
Zurück zum Zitat Agero Al, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657–670 CrossRefPubMed Agero Al, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657–670 CrossRefPubMed
2.
3.
Zurück zum Zitat Bernier J, Bonner J, Vermorken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142–149 CrossRefPubMed Bernier J, Bonner J, Vermorken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142–149 CrossRefPubMed
4.
Zurück zum Zitat Bolke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105–110 CrossRefPubMed Bolke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105–110 CrossRefPubMed
5.
Zurück zum Zitat Bonner JA, Ang K (2007) More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 357:1872–1873; author reply 1873 CrossRefPubMed Bonner JA, Ang K (2007) More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 357:1872–1873; author reply 1873 CrossRefPubMed
6.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578 CrossRefPubMed Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578 CrossRefPubMed
7.
Zurück zum Zitat Boone Sl, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159 CrossRefPubMed Boone Sl, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159 CrossRefPubMed
8.
Zurück zum Zitat Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514–515 CrossRefPubMed Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514–515 CrossRefPubMed
9.
Zurück zum Zitat Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176 CrossRefPubMed Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176 CrossRefPubMed
10.
Zurück zum Zitat Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174 CrossRefPubMed Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174 CrossRefPubMed
11.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345 CrossRefPubMed Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345 CrossRefPubMed
12.
Zurück zum Zitat Eilers RE Jr, Gandhi M, Patel JD et al (n d) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102:47–53 Eilers RE Jr, Gandhi M, Patel JD et al (n d) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102:47–53
13.
Zurück zum Zitat Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6:207–218 CrossRefPubMed Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6:207–218 CrossRefPubMed
14.
Zurück zum Zitat Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56:460–465 CrossRefPubMed Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56:460–465 CrossRefPubMed
15.
Zurück zum Zitat Gerber PA, Enderlein E, Homey B (2008) The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 26:2790–2792 CrossRefPubMed Gerber PA, Enderlein E, Homey B (2008) The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 26:2790–2792 CrossRefPubMed
16.
Zurück zum Zitat Gerber PA, Enderlein E, Homey B et al (2007) Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 25:4697–4698; author reply 4698–4699 CrossRefPubMed Gerber PA, Enderlein E, Homey B et al (2007) Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 25:4697–4698; author reply 4698–4699 CrossRefPubMed
17.
Zurück zum Zitat Gerber PA, Homey B (2008) Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 358:1175 CrossRefPubMed Gerber PA, Homey B (2008) Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 358:1175 CrossRefPubMed
18.
Zurück zum Zitat Giro C, Berger B, Bolke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166–171 CrossRefPubMed Giro C, Berger B, Bolke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166–171 CrossRefPubMed
19.
Zurück zum Zitat Giusti RM, Shastri KA, Cohen MH et al (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577–583 CrossRefPubMed Giusti RM, Shastri KA, Cohen MH et al (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577–583 CrossRefPubMed
20.
Zurück zum Zitat Graves JE, Jones BF, Lind AC et al (2006) Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 55:349–353 CrossRefPubMed Graves JE, Jones BF, Lind AC et al (2006) Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 55:349–353 CrossRefPubMed
21.
Zurück zum Zitat Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9:59–60 CrossRefPubMed Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9:59–60 CrossRefPubMed
22.
Zurück zum Zitat Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238–241 CrossRefPubMed Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238–241 CrossRefPubMed
23.
Zurück zum Zitat Kardaun SH, Van Duinen KF (2008) Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 33:46–49 PubMed Kardaun SH, Van Duinen KF (2008) Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 33:46–49 PubMed
24.
Zurück zum Zitat Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818 CrossRefPubMed Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818 CrossRefPubMed
25.
Zurück zum Zitat Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187 CrossRefPubMed Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187 CrossRefPubMed
26.
Zurück zum Zitat Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812 CrossRefPubMed Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812 CrossRefPubMed
27.
Zurück zum Zitat Lacouture ME, Mitchell EP, Piperdi B et al (n d) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357 Lacouture ME, Mitchell EP, Piperdi B et al (n d) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357
28.
Zurück zum Zitat Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107–119 CrossRefPubMed Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107–119 CrossRefPubMed
29.
30.
Zurück zum Zitat Mitra SS, Simcock R (2006) Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24:e28–e29 CrossRefPubMed Mitra SS, Simcock R (2006) Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24:e28–e29 CrossRefPubMed
31.
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966 CrossRefPubMed Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966 CrossRefPubMed
32.
Zurück zum Zitat Pongpudpunth M, Demierre MF, Goldberg LJ (2009) A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol 36:1303–1307 CrossRefPubMed Pongpudpunth M, Demierre MF, Goldberg LJ (2009) A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol 36:1303–1307 CrossRefPubMed
33.
Zurück zum Zitat Ricciardi S, Tomao S, De Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28–35 CrossRefPubMed Ricciardi S, Tomao S, De Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28–35 CrossRefPubMed
34.
Zurück zum Zitat Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232 CrossRefPubMed Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232 CrossRefPubMed
35.
Zurück zum Zitat Scope A, Agero Al, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390–5396 CrossRefPubMed Scope A, Agero Al, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390–5396 CrossRefPubMed
36.
Zurück zum Zitat Segaert S, Chiritescu G, Lemmens L et al (2009) Skin toxicities of targeted therapies. Eur J Cancer 45(Suppl 1):295–308 CrossRefPubMed Segaert S, Chiritescu G, Lemmens L et al (2009) Skin toxicities of targeted therapies. Eur J Cancer 45(Suppl 1):295–308 CrossRefPubMed
37.
Zurück zum Zitat Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433 CrossRefPubMed Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433 CrossRefPubMed
38.
Zurück zum Zitat Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132 CrossRefPubMed Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132 CrossRefPubMed
39.
Zurück zum Zitat Siena S, Peeters M, Van Cutsem E et al (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469–1474 CrossRefPubMed Siena S, Peeters M, Van Cutsem E et al (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469–1474 CrossRefPubMed
40.
Zurück zum Zitat Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010–1017 CrossRef Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010–1017 CrossRef
41.
Zurück zum Zitat Von Der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608 CrossRef Von Der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608 CrossRef
42.
Zurück zum Zitat Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921 CrossRefPubMed Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921 CrossRefPubMed
43.
Zurück zum Zitat Wollenberg A, Kroth J, Hauschild A et al (n d) Cutaneous side effects of EGFR inhibitors – appearance and management. Dtsch Med Wochenschr 135:149–154 Wollenberg A, Kroth J, Hauschild A et al (n d) Cutaneous side effects of EGFR inhibitors – appearance and management. Dtsch Med Wochenschr 135:149–154
44.
Zurück zum Zitat Wollenberg A, Moosmann N, Klein E et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790–792 CrossRefPubMed Wollenberg A, Moosmann N, Klein E et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790–792 CrossRefPubMed
45.
Zurück zum Zitat Wollenberg A, Moosmann N, Kroth J et al (2007) Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 58:615–618 CrossRefPubMed Wollenberg A, Moosmann N, Kroth J et al (2007) Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 58:615–618 CrossRefPubMed
Metadaten
Titel
Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors
Spektrum kutaner Nebenwirkungen
verfasst von
P.A. Gerber
B.A. Buhren
S. Kürle
Prof. Dr. B. Homey
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Die Dermatologie / Ausgabe 8/2010
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-010-1943-6

Weitere Artikel der Ausgabe 8/2010

Der Hautarzt 8/2010 Zur Ausgabe

Leitthema

Biologics

Übersichten

Psoriasistherapie

CME Weiterbildung · Zertifizierte Fortbildung

Antikoagulation in der Dermatologie

Dermatologie in Kunst und Geschichte

„Feuchtgebiete“

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Dermatologie und bleiben Sie gut informiert – ganz bequem per eMail.